Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4

Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, presented data

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today presented

Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Aurinia Reports First Quarter 2022 Financial and Operational Results: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports First Quarter 2022 Financial and Operational Results


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are

Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on

Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022

Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN)

Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentations at two upcoming investor conferences

Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended December 31, 2021. Amounts, unless specified otherwise

Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation at the 11th Annual Leerink Global Healthcare Conference (February

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.




  • H.C. Wainwright

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher: https://www.marketbeat.com/logos/articles/med_20230412102502_shockwave-medical-gets-10-jolt-leads-medical-gear.jpg
Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher

The old saying, “I’m from the government, I’m here to help,” is always intended as a punchline, but a Medicare rule changes sure did help shares of Shockwave Medical Inc. (NASDAQ: SWAV)

Shares

Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher: https://www.marketbeat.com/logos/articles/med_20230411111847_chart-tlry-4112023.png
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher

 

Tilray Brands (NASDAQ: TLRY) reported a mixed quarter and a deal to acquire HEXO that sent the market moving lower. While the news is less than spectacular, there are some takeaways for

Residential Prices, Rents Dip Across Qatar As World Cup Boost Dissipates: https://www.valuewalk.com/wp-content/uploads/2023/08/Rental-Rate-1.jpg
Residential Prices, Rents Dip Across Qatar As World Cup Boost Dissipates

Residential market declines amid supply surge, office market faces oversupply challenges, retail market competes with increasing pressure, and hotel occupancy falters despite spike in tourist

Techtronic Denies Short-Seller Jehoshaphat’s Fraud Allegations in Home Depot Business: https://www.valuewalk.com/wp-content/uploads/2023/02/Home-Depot-Stock-300x150.jpeg
Techtronic Denies Short-Seller Jehoshaphat’s Fraud Allegations in Home Depot Business

A second missive claiming ‘blemished’ channel misdoings are having little impact on Hong Kong-traded shares

Short-seller Jehoshaphat Research (JR) has accused Techtronic Industries (HKG:0669) of

Aphria Aktie: So greift Sie jetzt nach den Sternen
Aphria Aktie: So greift Sie jetzt nach den Sternen
Branchenvergleich Aktienkurs: Im Vergleich zur durchschnittlichen Jahresperformance von Aktien aus dem gleichen Sektor („Gesundheitspflege“) liegt Aphria mit einer Rendite von -16,88 Prozent mehr....
Canopy Growth-Aktie: Hilfe!
Canopy Growth-Aktie: Hilfe!
Sentiment und Buzz: Die Auswertung der Rate der Stimmungsänderung sowie der Diskussionsintensität ergibt folgendes Bild: Während des vergangenen Monats trübte sich die Stimmungslage der Anleger....
Aphria-Aktie: So macht Börse richtig Spaß!
Aphria-Aktie: So macht Börse richtig Spaß!
Technische Analyse: Aus den letzten 200 Handelstagen errechnet sich für die Aphria-Aktie ein Durchschnitt von 10,24 CAD für den Schlusskurs. Der Schlusskurs am letzten Handelstag lag bei 8,47 CAD....
Canopy Growth löst Glücksgefühle aus!
Canopy Growth löst Glücksgefühle aus!
Sentiment und Buzz: Die Auswertung der Rate der Stimmungsänderung sowie der Diskussionsintensität ergibt folgendes Bild: Während des vergangenen Monats trübte sich die Stimmungslage der Anleger....